Study of SCT520FF for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 80 years old.
- You have a confirmed diagnosis of wet age-related macular degeneration (nAMD) with active abnormal blood vessels in the study eye.
- The total size of the lesions in your study eye is about 12 optic disc areas or less.
- Your best corrected visual acuity in the study eye is between 19 and 73 letters on an eye chart.
- You do not have certain eye problems like tears in the retina layer, scars, or advanced dry spots affecting the center of vision.
- You have not had a heart attack, stroke, or blood clot event in the past 6 months, and your blood pressure is under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
Hear when a new nAMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.